For instance, DLL3, which is a promising target for SCLC treatment, with different compounds under development [21], is reportedly more expressed in the SCLC-A subtype [22], while an enhanced sensitivity to Aurora kinase inhibitors could be seen in the MYC-high NEUROD1-high SCLC subtype (SCLC-N) [23]. This evidence concerns the gene NEUROD1 and small cell lung carcinoma.